Cellectis Inc. (CLLS) Q1 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and welcome to the Selectus first quarter 2024 earnings call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. Please be aware that today's conference call is being recorded. I'd now like to turn the conference over to your first speaker, Arthur Strill, Interim Chief Financial Officer. You may begin. Good morning, and welcome, everyone, to Selectus' first quarter 2024 corporate update and financial results conference call. Joining me on the call today are Dr. André Choulika, our chief executive officer, and Dr. Mark Fertini, our chief medical officer. Yesterday evening, Selectus issued a 6K and a press release reporting our financial statements for the three-month period ending March 31, 2024, and a corporate and business update. The report and press release are available on our website at selectus.com. As a reminder, we will make statements regarding Selectus' financial outlook, including the sufficiency of cash-to-fund operations, in addition to its manufacturing, regulatory, and product development status, as well as product development status of its licensed partners. These forward-looking statements, which are based on our management's current expectations and assumptions, and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners, are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20F filed with the Security Exchange Commission, SEC, and the financial report, including the management report for the year ended on December 31st, 2023, and s...